摘要
Paclitaxel has long been a cornerstone chemotherapeutic agent in the treatment of several cancers, including breast and pancreatic malignancies. However, its potential is known to be limited by poor solubility and inefficient tumor delivery. Published in Nature Cancer (2025; doi.org/10.1038/s43018-025-01029-7), a new study details how researchers at the University of Arizona have developed a sphingolipid-derived paclitaxel nanovesicle, called the “paclitaxome,” that significantly improves pharmacokinetics, enhances tumor penetration, and reduces systemic toxicity in preclinical models. Led by Jianqin Lu, PhD, John A. and Frances P. Ware Endowed Associate Professor of Pharmaceutical Sciences at the University of Arizona R. Ken Coit College of Pharmacy, the research team demonstrated that this nanovesicle formulation outperformed the two FDA-approved paclitaxel products, Taxol and Abraxane, in both triple-negative breast cancer (TNBC) and pancreatic cancer models. According to Lu, the discovery represents a step toward safer and more effective drug delivery systems for difficult-to-treat cancers. He explained that one of the primary goals was to minimize adverse reactions that often accompany paclitaxel-based treatments. Designing a Smarter Nanocarrier Historically, traditional paclitaxel formulations have faced a trade-off between solubility and safety. Taxol uses Cremophor EL and ethanol as solubilizers but causes hypersensitivity reactions. Alternatively, Abraxane, an albumin-bound nanoparticle, offers a better safety profile but limited improvements in efficacy. To overcome these challenges, Lu's team engineered a self-assembling nanovesicle by conjugating paclitaxel to sphingomyelin, a natural phospholipid found in mammalian cell membranes. The chemical attachment created a stable bilayer structure that improved the drug's solubility, stability, and loading capacity. “Our paclitaxel is still a liposome formulation. So the difference compared to the traditional liposome is, in traditional liposome, the drug is physically encapsulated into the liposome,” Lu explained. “In our case, we chemically conjugate paclitaxel with a phospholipid or sphingolipid called sphingomyelin, so the drug is chemically attached into the bilayer of the liposome structure.” According to the study, the maximum tolerated dose (MTD) of paclitaxel increased from 20 mg/kg for Taxol and 40 mg/kg for paclitaxel physically laden liposome to as high as 70-100 mg/kg for the new paclitaxome. Of note, mice treated with the nanovesicle formulation exhibited minimal weight loss and no evidence of myelosuppression or neuropathy, two of paclitaxel's most problematic side effects. Improving Tumor Penetration & Drug Retention Despite higher drug loading and stability, Lu noted that nanocarriers often struggle to penetrate deeply into tumor tissue. The team addressed this limitation by engineering a cationization-enabled transcytosis mechanism through the integration of an ultra-pH-sensitive azepane (AZE) probe. The AZE probe responds to the mildly acidic tumor microenvironment (pH ~6.5) by reversing the surface charge of the nanovesicle from negative to positive. This charge conversion enhances adsorption-mediated endocytosis and transcytosis, allowing the nanocarrier to move more effectively through tumor layers. “The reason why we selected the azepane is because of its specific pKa,” Lu affirmed. “In the tumor microenvironment, the pH is acidic, around 6.5. Under that acidic pH, the AZE can be easily ionized and flip the charge from negative to positive. The positive-charged nanoparticle will interact with the negatively charged cancer-cell surface to enable this adsorption-mediated deep tumor penetration.” In cellular and three-dimensional tumor spheroid models, the AZE-enabled paclitaxome also demonstrated significantly improved uptake and diffusion compared to non–pH-responsive controls. As detailed in the study, the nanovesicle's internalization was primarily mediated through caveolae-dependent endocytosis, with trafficking through the Golgi apparatus facilitating efficient transcellular transport. “The major bottleneck for the tumor delivery of nanomedicine is in the tumor microenvironment,” Lu noted. “The interstitial fluid pressure induces strong resistance for drugs to transport or diffuse, and the extracellular matrix further blocks effective delivery.” He shared that the charge-reverse intelligent nanoparticle can facilitate this deep tumor penetration by overcoming those barriers, like interstitial fluid pressure and extracellular matrix. This then leads to more tumor uptake. Enhancing Circulation Time & Avoiding Immune Clearance Another major advancement in Lu's design was the use of a CD47 “self” peptide coating to replace traditional polyethylene glycol (PEG) shielding. While PEGylation has long been used to extend nanoparticle circulation times, repeated exposure can trigger anti-PEG immune responses that accelerate clearance. “CD47 is a protein that exists on the surface of red blood cells and other healthy cells. It sends a signal to macrophages that says, ‘Don't eat me,’” Lu explained. “So if we coat our nanoparticle with CD47 peptide, it can escape macrophage phagocytosis. That means it can stay in the circulation longer and deliver more drug to the tumor.” According to the research, the CD47-coated, pH-sensitive paclitaxome exhibited a 1.67-fold longer half-life and a 2.4-fold higher tumor drug accumulation compared to PEGylated versions. The combined AZE and CD47 modifications reduced drug distribution to non-tumor tissues, improving therapeutic selectivity and efficacy. Redefining Performance Among Nanocarriers When compared against leading paclitaxel formulations, including Taxol, Abraxane, and other experimental nanocarriers such as chimeric polypeptide–paclitaxel (CP-PTX) and poly(γ-l-glutamylglutamine)-paclitaxel (PGG-PTX), the CD47p/AZE-paclitaxome consistently demonstrated superior pharmacokinetics and antitumor activity. In a triple-negative breast cancer model (4T1-Luc2), the nanovesicle nearly eliminated tumor growth and metastasis to the lungs, the research states. In an advanced pancreatic cancer model (KPC-Luc), the formulation significantly extended survival and reduced metastatic burden compared with all other paclitaxel-based treatments. “Through the use of CD47 self peptide, we can reduce the distribution of the nanoparticle to healthy tissues,” Lu said. “So less of the chemotherapy drug reaches healthy tissues. That's one reason we can reduce toxicity at much higher doses. The chemical conjugation strategy also helps because it requires specific tumor stimuli to release the drug, which further reduces systemic toxicity.” Optimizing Combination Therapies Beyond monotherapy, Lu's team sought to test whether the paclitaxome platform could improve combination treatments, specifically paclitaxel plus gemcitabine for pancreatic cancer and paclitaxel plus carboplatin for TNBC. “Paclitaxel plus gemcitabine or paclitaxel plus carboplatin are standard care for treating breast cancer or pancreatic cancer,” Lu said. “That's why we want to co-deliver these two drugs with the paclitaxel platform. Through this chemical conjugation and physical loading, we can coordinate the drug release and achieve synergistic efficacy while reducing toxicity.” By identifying the optimal synergistic ratios (2:1 for paclitaxel to gemcitabine and 4:1 for paclitaxel to carboplatin), the researchers were able to encapsulate both drugs within the nanovesicle without compromising their stability or size. Co-encapsulation of gemcitabine and paclitaxel led to a 10.4-fold increase in half-life, a 230-fold increase in area under the curve, and nearly 30-fold higher tumor accumulation compared to conventional combination therapy. As presented in the research, these results correlated with significant reductions in metastatic lesions and enhanced survival. Further, in the postsurgical TNBC recurrence model, the co-delivery of paclitaxel and carboplatin with CD47p/AZE–paclitaxome reduced tumor regrowth to just 35% of its pre-surgical size and markedly extended survival. “We use chemical conjugation to attach the drug into a phospholipid that has been used in liposome formulation,” Lu said. “The nanocarrier itself is a drug. To have more effective combination chemotherapy, we just need to load the second drug through physical entrapment, which simplifies the process.” Proving the Platform Works Beyond Paclitaxel To test whether this approach could be generalized to other drugs, the team applied the same sphingomyelin, AZE, and CD47p design to camptothecin, another hydrophobic anticancer agent. The resulting formulation, termed “camptothesome,” showed improved stability, pH responsiveness, and tumor targeting. In mouse models of pancreatic cancer, the CD47p/AZE–camptothecin achieved higher tumor accumulation and outperformed free camptothecin and Onivyde, an FDA-approved liposomal irinotecan formulation. “I think this strategy is pretty versatile,” Lu said. “In addition to paclitaxel, we already extended this technology to other drugs like doxorubicin or platinum-based drugs. As long as the drug has a functional group like hydroxyl, carboxyl, or amine, we can easily attach it to the sphingomyelin because sphingomyelin has a hydroxyl group that enables drug conjugation.” The Pathway to Clinical Development While the current study was conducted in preclinical models, Lu believes the findings lay a strong foundation for future clinical development. “I think most nanoparticle formulations face one common issue with clinical translation, which is the scale-up,” Lu said. “We can optimize the design in small-scale, but that may not work for large batch production needed for clinical trials. We already launched large-scale preparation using ethanol injection technology and manufactured enough for about 100 patients.” Lu added that while manufacturing progress continues, his team is also exploring new therapeutic possibilities for the platform. The potential for the paclitaxome platform extends beyond oncology. The nanovesicle's ability to carry both small molecules and biologics means it could be adapted for use in other therapeutic areas where precise delivery and controlled release are essential. “In addition to oncology, we're actively investigating other diseases like Alzheimer's and Parkinson's,” Lu said. “Those are neurodegenerative diseases that require crossing the blood-brain barrier. We're also studying brain tumors like glioblastoma, which need deep tissue penetration for effective therapy.” Clinical Application Looking ahead, the study's findings could have broad implications for cancer treatment, particularly for tumors known to resist traditional chemotherapy. Lu emphasized that integrating targeted delivery with combination therapy may help overcome multiple barriers simultaneously. “Paclitaxel itself, although it's a chemo, also has immunogenic cell death potential,” Lu said. “That's a unique type of cancer cell death mechanism during which cytotoxic T cells can be recruited and activated in the tumor site. So that's how we can potentially synergize with other immunotherapy drugs like immune checkpoint inhibitors.” He explained that the combination of sphingolipid conjugation, pH-responsive cationization, and immune evasion through CD47 coating provides a versatile template for nanomedicine design. “What we found right now is paclitaxel tends to switch immune-cold TNBC and pancreatic cancer into a hot, inflamed type with many inflammatory molecules induced or activated in TNBC and pancreatic cancer,” Lu said. “That allows us to further enhance immune checkpoint inhibitor efficacy because we can specifically upregulate PD-1 and PD-L1 levels in these two immune-cold cancers.” Ultimately, Lu and his research team have developed a delivery system that enhances the efficacy and safety of paclitaxel-based therapies. The sphingolipid-derived paclitaxome improves tumor targeting, avoids immune clearance with CD47 coating, and enables safe co-delivery of multiple drugs. If successfully translated into the clinic, this innovation could reshape how oncologists approach combination chemotherapy for tumors that are notoriously hard to treat. The paclitaxome platform offers a promising framework for building the next generation of targeted nanomedicines that deliver higher precision and improved patient outcomes. Lindsey Nolen is a contributing writer.